Differences

This shows you the differences between two versions of the page.

--- home:translations:french [03.12.2019] – [Les points de terminaison de la Protocole] sallieq
+++ home:translations:french [05.10.2019] – [Data] sallieq
@@ Line 292: / Line 292: @@
     * Signes de la résolution sur l'inflammation CT et IRM
-==== Data ====
-[[home:patients:cohort_statistics#later_information_2013|Success rates for various Dx, compiled in 2013]]
 =====  Arrêt du Protocole =====
@@ Line 314: / Line 312: @@
 Les patients qui cessent de l'olmésartan se terminent leur rétablissement.
+===== Data =====
+[[home:patients:cohort_statistics#later_information_2013|Success rates for various Dx, compiled in 2013]]
+[[home:food:aim_health:aging|Olmesartan research]]
+==== Response in 5 diagnoses ====
+ TOTALS: 864 members;573 report success; 119 report no success; and for 172 results are not clear.
+SUCCESS RATES: Over all success rate 66.32% Over all unsuccessful 13.77% Over all unsure 19.91%
+Sarcoidosis success 75.8%
+Chronic Fatigue Syndrome success 60.1%
+Lyme disease success 66.9%
+Rheumatoid arthritis success 69.2%
+Fibromyalgia success 64.2%
+All Other Th1 disease success 59.8%
 ===== Notes and comments =====

home/translations/french.txt · Last modified: 09.14.2022 by 127.0.0.1